<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ibandronate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ibandronate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ibandronate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11495" href="/d/html/11495.html" rel="external">see "Ibandronate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F181336"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Boniva [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F181350"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Bisphosphonate Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F181338"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Avoid use of oral ibandronate in patients with swallowing difficulties, esophageal motility disorders, or the inability to stand or sit upright for ≥60 minutes. When appropriate, correct hypocalcemia and vitamin D deficiency (eg, to a 25-hydroxyvitamin D level ≥20 ng/mL [≥50 nmol/L]) prior to initiating therapy and ensure adequate calcium and vitamin D intake during therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30907953','lexi-content-ref-34448749','lexi-content-ref-12686715','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30907953','lexi-content-ref-34448749','lexi-content-ref-12686715','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c97998a-dc32-487f-833f-bd62529cc9fc">Breast cancer, metastatic bone disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, metastatic bone disease (treatment; off-label use): IV: </b>6 mg over 1 to 2 hours every 3 to 4 weeks for up to 4 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12954579','lexi-content-ref-15251160','lexi-content-ref-17163265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12954579','lexi-content-ref-15251160','lexi-content-ref-17163265'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d651d917-5b3e-4644-84f8-f0afb2d722ca">Hypercalcemia of malignancy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypercalcemia of malignancy (albumin-corrected serum calcium ≥12 mg/dL [≥3 mmol/L]) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May also be used at the same doses for treatment of hypercalcemia due to excessive bone resorption from other causes (eg, granulomatous diseases, hyperparathyroidism, vitamin D intoxication) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26037642','lexi-content-ref-Shane.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26037642','lexi-content-ref-Shane.2022'])">Ref</a></span>). Asymptomatic or mildly symptomatic patients with chronic hypercalcemia may not require immediate treatment unless albumin-corrected serum calcium level is &gt;14 mg/dL (&gt;3.5 mmol/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Shane.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Shane.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 to 6 mg as a single dose over 1 to 2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12783289','lexi-content-ref-9010041']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12783289','lexi-content-ref-9010041'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d9f9404a-881f-44e5-b401-a29892cf1625">Osteoporosis, postmenopausal, fracture risk reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis, postmenopausal, fracture risk reduction: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used in patients at risk for vertebral fractures; use has not been associated with reduction in hip or nonvertebral fractures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26350171','lexi-content-ref-30907953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26350171','lexi-content-ref-30907953'])">Ref</a></span>). Prior to use, evaluate and treat any potential causes of secondary osteoporosis (eg, severe vitamin D deficiency) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25182228'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients with high fracture risk, including those with a history of vertebral fragility fracture, </i>
<b>
<i>or</i></b>
<i> those with a T-score of −2.5 or lower or a T-score between −1 and −2.5 at high fracture risk according to a risk assessment</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25182228'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Treatment:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 150 mg once monthly.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 3 mg every 3 months.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients without high fracture risk, including those with a T-score between −1 and −2.5 and who are </i>
<b>
<i>not</i></b>
<i> at high fracture risk according to a risk assessment, but who desire pharmacologic therapy to prevent bone loss or fracture </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lewiecki.1','lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lewiecki.1','lexi-content-ref-25182228'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Prevention: Oral:</b> 150 mg once monthly.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy:</b> The optimal duration of therapy has not been established. If discontinued, the decision to resume therapy is based on multiple factors, including decline in bone mineral density and risk factors for fracture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26350171','lexi-content-ref-30907953','lexi-content-ref-20173017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26350171','lexi-content-ref-30907953','lexi-content-ref-20173017'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d53e3810-e0c9-431d-8546-5a0a4ab1bd2c">Prostate cancer, metastatic, bone pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, metastatic, bone pain (alternative agent if radiation therapy is not an option; off-label use):</b>
<b>IV:</b> 6 mg as a single dose over 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26242893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26242893'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Missed doses:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Oral</b> (once-monthly):</i> If an oral dose is missed, administer the next morning after remembered if the next month's scheduled dose is &gt;7 days away. If the next month's scheduled dose is within 7 days, wait until the next month's scheduled dose. Then return to the original scheduled day of the month on the once-monthly schedule; however, do not administer &gt;150 mg within 7 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>IV</b> (once every 3 months):</i> If an IV dose is missed, administer as soon as it can be rescheduled. Thereafter, administer every 3 months from the date of the last injection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991574"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Osteoporosis: Oral, IV:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Use is not recommended.</p></div>
<div class="block doha drugH1Div" id="F50988742"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, ibandronate does not undergo hepatic metabolism.</p></div>
<div class="block doe drugH1Div" id="F181339"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F56157566"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Atypical femur fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Atypical <b>femur fractures</b> (AFF) have been reported with bisphosphonate use, including ibandronate. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). The benefits of therapy (when used for osteoporosis) generally outweigh the absolute risk of AFF within the first 5 years of treatment, especially in patients with high fracture risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26350171','lexi-content-ref-30907953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26350171','lexi-content-ref-30907953'])">Ref</a></span>). The risk decreases after bisphosphonate discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32813950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32813950'])">Ref</a></span>). AFF is estimated to occur in ~0.2% of bisphosphonate users after ≥5 years of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21343577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21343577'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related. Long-term suppression of bone turnover may be primarily responsible; however, micro-damage accumulation and alterations of collagen cross-linking have also been postulated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23712442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23712442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; most fractures have occurred in patients receiving bisphosphonates for at least 3 to 5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31893493','lexi-content-ref-21343577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31893493','lexi-content-ref-21343577'])">Ref</a></span>). Patients may experience prodromal pain weeks or months before the fracture occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20842676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20842676'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Long-term treatment (&gt;3 to 5 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2010'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Asian race (in North America) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32813950','lexi-content-ref-23712442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32813950','lexi-content-ref-23712442'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Femoral bowing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30169557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30169557'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Glucocorticoid use (&gt;1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30169557','lexi-content-ref-32813950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30169557','lexi-content-ref-32813950'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI mucosal irritation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Esophagitis, dysphagia, esophageal ulcer, erosive esophagitis, esophageal stenosis (rare), and esophageal perforation (rare) have been reported with other bisphosphonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21736407','lexi-content-ref-22778283','lexi-content-ref-21343270','lexi-content-ref-24287510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21736407','lexi-content-ref-22778283','lexi-content-ref-21343270','lexi-content-ref-24287510'])">Ref</a></span>). Oropharyngeal ulcer has also been noted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20674418','lexi-content-ref-21816532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20674418','lexi-content-ref-21816532'])">Ref</a></span>). Ibandronate appears to be well tolerated from a GI reaction standpoint (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19318598','lexi-content-ref-19851511','lexi-content-ref-18498910']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19318598','lexi-content-ref-19851511','lexi-content-ref-18498910'])">Ref</a></span>). However, reactions may represent a class effect, including oral ibandronate. Experiencing a GI event increases the likelihood of decreased adherence at 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27112533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27112533'])">Ref</a></span>) or discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16678644','lexi-content-ref-12947959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16678644','lexi-content-ref-12947959'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: GI mucosal irritation is secondary to the local effect on the gastric mucosa (as opposed to a systemic effect) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15765619','lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15765619','lexi-content-ref-21504254'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; dependent upon the type of mucosal injury but case reports have noted onset within 2 days to 12 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21736407','lexi-content-ref-21816532','lexi-content-ref-22778283','lexi-content-ref-21343270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21736407','lexi-content-ref-21816532','lexi-content-ref-22778283','lexi-content-ref-21343270'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Oral administration (versus IV administration) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15765619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15765619'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Incorrect administration technique (oral only) (ie, &lt;180 mL water, lying down after administration) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254','lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254','lexi-content-ref-19570737'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent nonsteroidal anti-inflammatory drug or antithrombotic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254','lexi-content-ref-30626809']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254','lexi-content-ref-30626809'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior GI issues (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25866298']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25866298'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypocalcemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">While transient <b>hypocalcemia</b> is expected with the use of ibandronate (and all bisphosphonates) secondary to their mechanism of action, cases of symptomatic hypocalcemia are rare with oral ibandronate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19570737'])">Ref</a></span>). Intravenous ibandronate can cause both asymptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9157773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9157773'])">Ref</a></span>) and symptomatic hypocalcemia. Hypocalcemia is typically quickly reversible with either discontinuation of ibandronate or use of supportive care measures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19570737'])">Ref</a></span>). In a systematic review of clinically significant hypocalcemia in patients receiving IV bisphosphonates for bone metastases (including ibandronate), incidence ranged from 1% to 2% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32535678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32535678'])">Ref</a></span>). When compared to pamidronate, IV ibandronate appears to have a higher incidence of hypocalcemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12783289']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12783289'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: By decreasing osteoclast activity, calcium is not released into the bloodstream, causing a transient decrease in blood calcium. In patients with normally functioning parathyroid glands, calcium homeostasis is regained shortly after starting the bisphosphonate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19570737'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: IV: Rapid; hypocalcemia can occur within the first few days after IV infusion of ibandronate. Oral: Intermediate; hypocalcemia typically occurs within weeks of the start of oral ibandronate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19570737'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline hypocalcemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired parathyroid function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• IV bisphosphonate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Vitamin D deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254','lexi-content-ref-12686715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254','lexi-content-ref-12686715'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypomagnesemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16547070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16547070'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications (eg, interferon-alfa, aminoglycosides, loop diuretics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16547070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16547070'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Close dosing intervals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16547070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16547070'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Influenza-like illness/acute phase reaction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute phase reaction-like symptoms/flu-like symptoms</b> are not life-threatening, reversible, and typically either not observed beyond the first dose of the bisphosphonate or symptoms are less significant with subsequent exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>). While more common when bisphosphonates are used IV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16729277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16729277'])">Ref</a></span>), it has also been documented with oral use of ibandronate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16007327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16007327'])">Ref</a></span>). The reaction can manifest as influenza-like symptoms, such as fatigue, arthralgia, and bone pain as well as fever and rigors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19570737'])">Ref</a></span>). Resolution is usually observed within 2 to 3 days after symptom onset but may last up to 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28299378','lexi-content-ref-23184667']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28299378','lexi-content-ref-23184667'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Appears to be mediated by interleukin-6, tumor necrosis factor (TNF)-alpha, and other pro-inflammatory cytokines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18045781','lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18045781','lexi-content-ref-19570737'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; typically manifests within the first 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3124942','lexi-content-ref-21504254','lexi-content-ref-18045781','lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3124942','lexi-content-ref-21504254','lexi-content-ref-18045781','lexi-content-ref-19570737'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• IV dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16729277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16729277'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Nitrogen-containing bisphosphonates (eg, ibandronate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19570737'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Less frequent oral dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19570737'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Osteonecrosis of the jaw</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteonecrosis of the jaw</b> (ONJ) was first described in the dental literature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12966493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12966493'])">Ref</a></span>) with the use of IV bisphosphonates, and several case reports of ONJ with IV ibandronate exist. However, there is conflicting evidence of whether this risk is seen with oral bisphosphonates or is simply an increased risk in those who are treated with agents for osteoporosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16873439']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16873439'])">Ref</a></span>). ONJ is most commonly reversible and not life-threatening; however, the possibility of ONJ significantly increases the risk of nonadherence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28602783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28602783'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; exact mechanism unknown, but several hypothesized mechanisms exist, such as over-suppression of bone turnover (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16243172']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16243172'])">Ref</a></span>), mucosal toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16454811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16454811'])">Ref</a></span>), cytokine-mediated inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17614762']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17614762'])">Ref</a></span>), and infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19371816','lexi-content-ref-25710950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19371816','lexi-content-ref-25710950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; can be spontaneous or after insult, such as tooth extraction and/or dental implant procedures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Alcohol use disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Anemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30393090'])">Ref</a></span>)()</p>
<p style="text-indent:-2em;margin-left:6em;">• Cancer and anticancer therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Corticosteroid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dental extraction and/or dental implant procedures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640','lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640','lexi-content-ref-30393090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30393090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Extended duration (&gt;3 years) of bisphosphonate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High-dose, IV bisphosphonate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunological disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30393090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Oral surgery or trauma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Poor oral hygiene (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Poorly fitting dental appliance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Radiotherapy to head and neck (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30393090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Tobacco smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F181309"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (oral: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (5% to 8%), constipation (3% to 4%), diarrhea (3% to 5%), dyspepsia (4% to 6%), gastritis (IV: 2%), gastroenteritis (IV: 2%), nausea (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (IV: 2%), urinary tract infection (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Acute phase reaction-like symptoms (9% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (4% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (IV: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (IV: 1%), dizziness (2%), fatigue (IV: 3%), headache (3% to 4%), insomnia (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (6% to 10%), back pain (5% to 7%), limb pain (3% to 4%), localized osteoarthritis (2% to 3%), muscle cramps (oral: 2%), myalgia (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (2% to 3%), flu-like symptoms (2% to 5%), nasopharyngitis (3% to 4%), upper respiratory tract infection (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Ophthalmic<b>: </b>Scleritis, uveitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Prolonged QT interval on ECG (Bonilla 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous dermatitis, erythema multiforme (Song 2019), Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia (Papapetrou 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Femur fracture (diaphyseal or subtrochanteric) (Park-Wyllie 2011), musculoskeletal pain (bone, joint, or muscle; incapacitating), osteonecrosis (oro-facial sites including the external auditory canal), osteonecrosis of the jaw (Lewiecki 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Iritis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, exacerbation of asthma</p></div>
<div class="block coi drugH1Div" id="F181322"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Known hypersensitivity to ibandronate or any component of the formulation; hypocalcemia; oral tablets are also contraindicated in patients unable to stand or sit upright for at least 60 minutes and in patients with abnormalities of the esophagus which delay esophageal emptying, such as stricture or achalasia.</p></div>
<div class="block war drugH1Div" id="F181307"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone/joint/muscle pain: Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Discontinue intravenous ibandronate therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with the same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Allergic reactions, including anaphylactic reaction/shock (some fatal), angioedema, bronchospasm, exacerbation of asthma, rash, Stevens-Johnson syndrome, erythema multiforme, and dermatitis bullous have been reported; discontinue if hypersensitivity reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: Uveitis and scleritis have been reported with ibandronate; patients presenting with signs of ocular inflammation may require further ophthalmologic evaluation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: Altered absorption and ulceration risk: Avoid oral bisphosphates after bariatric surgery; inadequate oral absorption and potential anastomotic ulceration may occur. If therapy is indicated, IV administered bisphosphonates are recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use not recommended with severe renal impairment (CrCl &lt;30 mL/minute). Intravenous bisphosphonate use has been associated with renal deterioration, including acute renal failure.</p></div>
<div class="block foc drugH1Div" id="F181317"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Boniva: 3 mg/3 mL (3 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 3 mg/3 mL (3 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Boniva: 150 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg</p></div>
<div class="block geq drugH1Div" id="F181305"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F3422242"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ibandronate Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg/3 mL (per mL): $166.67 - $168.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ibandronate Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $138.73 - $165.12</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F181319"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer 60 minutes before the first food or drink of the day (other than water) and prior to taking any oral medications or supplements (eg, calcium, antacids, vitamins). Ibandronate should be taken in an upright position with a full glass (6 to 8 oz) of plain water and the patient should avoid lying down for 60 minutes to minimize the possibility of GI side effects. Mineral water with a high calcium content should be avoided. The tablet should be swallowed whole; do not chew or suck. Do not eat or drink anything (except water) for 60 minutes following administration of ibandronate.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer as a 15 to 30 second bolus IV; avoid paravenous or intraarterial administration (may cause tissue damage). Do not mix with calcium-containing solutions or other drugs. For osteoporosis, do not administer more frequently than every 3 months.</p>
<p style="text-indent:-2em;margin-left:4em;">Off-label rates: Infuse over 1 to 2 hours for metastatic bone disease due to breast cancer and for hypercalcemia of malignancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12954579','lexi-content-ref-12783289','lexi-content-ref-9010041']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12954579','lexi-content-ref-12783289','lexi-content-ref-9010041'])">Ref</a></span>). Infuse over 15 minutes for metastatic bone pain due to prostate cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26242893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26242893'])">Ref</a></span>).</p></div>
<div class="block meg drugH1Div" id="F11441255"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:0em;">Boniva injection: <a href="/external-redirect?target_url=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2016%2F021858s022lbl.pdf%23page%3D18&amp;token=ra7janPAv1YRrOFAM9BKIIpVLIej0Z1yDSS%2FbJV%2FMED4NQFxjYstit4gdCjFPT3E1ZDsUyoVqHRINNlUA93bvjilTLXjJUSIVG96xz0s4cnXUfsl6EQEZ375JNOXd9G1&amp;TOPIC_ID=8887" target="_blank">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021858s022lbl.pdf#page=18</a></p>
<p style="text-indent:-2em;margin-left:4em;margin-top:0em;">Boniva tablets: <a href="/external-redirect?target_url=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2016%2F021455s021lbl.pdf%23page%3D19&amp;token=86rBLf3OKRSpaeoka%2B6JAlhyBo0nJ8JrH5Q4cl6JSHt0uoJ1vRpBkFtNgZnHvEYS8r7lQ52VknKapadvbeXIjT6lT%2BRPxEK6fCy77SoJbBgYuouIAkb81EDVHD%2BCOXg9&amp;TOPIC_ID=8887" target="_blank">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021455s021lbl.pdf#page=19</a></p></div>
<div class="block use drugH1Div" id="F181318"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis, postmenopausal, fracture risk reduction: </b>Treatment and prevention of postmenopausal osteoporosis.</p></div>
<div class="block off-label drugH1Div" id="F25474814"><span class="drugH1">Use: Off-Label: Adult</span><p>Breast cancer, metastatic bone disease (treatment); Hypercalcemia of malignancy; Prostate cancer, metastatic, bone pain (alternative agent)</p></div>
<div class="block cyt drugH1Div" id="F13299500"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F181311"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives. Aminoglycosides may enhance the nephrotoxic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiogenesis Inhibitors (Systemic): May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capecitabine: Bisphosphonate Derivatives may enhance the nephrotoxic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May diminish the therapeutic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyvalent Cation Containing Products: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F181332"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food may reduce absorption; mean oral bioavailability is decreased up to 90% when given with food. Management: Take with a full glass (6-8 oz) of plain water, at least 60 minutes prior to any food, beverages, or medications. Mineral water with a high calcium content should be avoided. Wait at least 60 minutes after taking ibandronate before taking anything else.</p></div>
<div class="block rep_considerations drugH1Div" id="F49307599"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Underlying causes of osteoporosis should be evaluated and treated prior to considering bisphosphonate therapy in premenopausal women; effective contraception is recommended when bisphosphonate therapy is required (Pepe 2020). Bisphosphonates are incorporated into the bone matrix and gradually released over time. Because exposure prior to pregnancy may theoretically increase the risk of fetal harm, most sources recommend discontinuing bisphosphonate therapy in females of reproductive potential as early as possible prior to a planned pregnancy. Use in premenopausal females should be reserved for special circumstances when rapid bone loss is occurring; a bisphosphonate with the shortest half-life should then be used (Bhalla 2010; Pereira 2012; Stathopoulos 2011).</p></div>
<div class="block pri drugH1Div" id="F181324"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">It is not known if bisphosphonates cross the placenta, but based on their lower molecular weight, fetal exposure is expected (Djokanovic 2008; Stathopoulos 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Information related to the use of ibandronate in pregnancy is limited (El-Safadi 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Bisphosphonates are incorporated into the bone matrix and gradually released over time. The amount available in the systemic circulation varies by drug, dose, and duration of therapy. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy (hypocalcemia, low birth weight, and decreased gestation have been observed in some case reports); however, available data have not shown that exposure to bisphosphonates during pregnancy significantly increases the risk of adverse fetal events (Djokanovic 2008; Green 2014; Levy 2009; Machairiotis 2019; Sokal 2019; Stathopoulos 2011). Exposed infants should be monitored for hypocalcemia after birth (Djokanovic 2008; Stathopoulos 2011).</p></div>
<div class="block brc drugH1Div" id="F20471831"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ibandronate is present in breast milk.</p></div>
<div class="block dic drugH1Div" id="F181325"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Ensure adequate calcium and vitamin D intake; if dietary intake is inadequate, dietary supplementation is recommended. Patients should consume:</p>
<p style="text-indent:-2em;margin-left:4em;">Calcium: 1,000 mg/day (males: 50 to 70 years of age) <b>or</b> 1,200 mg/day (females ≥51 years of age and males ≥71 years of age) (IOM 2011; NOF [Cosman 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">Vitamin D: 800 to 1,000 units daily (age ≥50 years) (NOF [Cosman 2014]). Recommended dietary allowance (RDA): 600 units daily (age ≤70 years) <b>or</b> 800 units daily (age ≥71 years) (IOM 2011).</p></div>
<div class="block mop drugH1Div" id="F181315"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Osteoporosis: Serial bone mineral density (BMD) should be evaluated at baseline and every 1 to 3 years on treatment (usually at ~2 years following initiation of therapy, then more or less frequently depending on patient-specific factors and stability of BMD) (AACE/ACE [Camacho 2020]; ES [Eastell 2019]; NOF [Cosman 2014]); evaluate BMD every 2 to 4 years during a drug holiday (ES [Eastell 2019]); serum creatinine prior to each IV dose; annual measurements of height and weight, assessment of chronic back pain; serum calcium (prior to and during therapy) and 25(OH)D; may consider measuring biochemical markers of bone turnover (eg, fasting serum CTX or urinary NTX) at baseline, 3 months, and 6 months, to assess treatment response, adherence to therapy, and/or possible malabsorption (ES [Eastell 2019]); femur fracture in patients presenting with thigh or groin pain (during or after treatment; if fracture identified, also evaluate contralateral limb).</p></div>
<div class="block pha drugH1Div" id="F181306"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">A bisphosphonate which inhibits bone resorption via actions on osteoclasts or on osteoclast precursors; decreases the rate of bone resorption, leading to an indirect increase in bone mineral density.</p></div>
<div class="block phk drugH1Div" id="F181321"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Terminal V<sub>d</sub>: 90 L; 40% to 50% of circulating ibandronate binds to bone</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 85.7% to 99.5%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not metabolized</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: Minimal; reduced ~90% following standard breakfast</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 150 mg dose: Terminal: 37 to 157 hours</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Terminal: ~5 to 25 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Oral: 0.5 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (50% to 60% of absorbed dose, excreted as unchanged drug); feces (unabsorbed drug)</p></div>
<div class="block phksp drugH1Div" id="F51159804"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Patients with CrCl 40 to 70 mL/minute had 55% higher AUC and patients with CrCl 30 mL/minute had more than a 2-fold increase in exposure.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Progressive age-related changes in renal function may alter the elimination of ibandronate in elderly patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F854895"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Adromux | Bandrobon | Bantuc | Brexell plus | Elasterin | Femorel | Fijacal | Ibandronato Richet | Ibanleg | Intersules | Mesel | Modifical | Oseum | Osteotrex | Posclim | Silidral uno | Tabtil</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva | Ibandronic acid accord | Ibandronsaeure ratiopharm | Ibandronsaeure sandoz | Osteonat | Osteoviva</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Bondronat</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Bonaid | Boncare | Bondrix | Bondrova | Bone guard | Bonfix | Bonmax | Bonova | Droniva | Ibandron | Idrofos | Ivana | Maxbon | Ostiban</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva | Ibandronate Apotex | Ibandronate eg | Ibandronate Mylan | Ibandronic acid accord | Ibandronic acid sandoz | Ibandronic acid teva | Mirdezel | Quodixor</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Femorel</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva | Iasibon | Ibandronic acid | Ibandronic acid teva | Ivadron | Kefort | Osbonelle | Ossica | Quodixor</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Afrat | Bonviva | Iban | Iband | Ibandronato de sodio | Ibandronato de sodio monoidratado | Ibaness | Ibanuno | Osbant | Osteoban | Osteotec | Sintezys</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva | Ibandronat Actavis | Ibandronat helvepharm osteo | Ibandronat Mepha | Ibandronat Sandoz | Ibandronat spirig hc</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Bonviva | Femorel</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Adromux | Bondronat | Bonviva | Dronaval | Ibadrox | Ibanox | Idena | Recaxin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai ben | Bondronat | Ibandronate monoso | Jia nuo shun</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acido ibandronico | Bandro | Bandro o | Bonames | Bondronat | Bonviva | Conaciban o | Droniban | Ibanat | Ibandromas | Ibandromet | Ibandron | Ibandronato | Ibanic | Idena | Meliba | Oseban | Osteocalcit | Osteolong | Unomes</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Flastin | Gerousia | Holmevis | Iasibon | Ibandronat Apotex | Ibandronat Mylan | Ibandronic acid accord | Ibandronic acid aurobindo | Ibandronic acid sandoz | Ibandronic acid stada | Ibandronic acid teva | Ikametin | Licobondrat | Osagrand | Phacebonate</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonoste | Bonviva | Iasibon | Ibandronate | Ibandronic acid accord | Ibandronsaeure | Ibandronsaeure 1A pharma | Ibandronsaeure actavis | Ibandronsaeure AL | Ibandronsaeure Cell pharm | Ibandronsaeure CT | Ibandronsaeure Hexal | Ibandronsaeure Ibisqus | Ibandronsaeure Juta | Ibandronsaeure Onkovis | Ibandronsaeure ratiopharm | Ibandronsaeure sandoz | Ibandronsaeure Stada | Ribobandron</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Acido ibandronico | Adromux | Bandrocare aglf | Bifosfan | Bondronat | Bonviva | Denual | Ibandronato mamey | Ibandronato mk | Idena | Ipexal | Osteox | Recaxin | Unoiban</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Aciberkan | Acido ibandronico | Bonames | Bondronat | Denual | Dronaval | Femorel | Ibandromet | Ibandronato mk | Ibandrox | Ibanflex | Ibrac | Idena | Oseban | Recaxin | Rubir</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Baxogar | Ibandronic acid accord | Ibandronic acid teva | Ossica</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Bonprove | Ibandrocare</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Abrion | Acido ibandronico actavis | Acido ibandronico alter | Acido ibandronico amneal | Acido ibandronico apotex | Acido ibandronico aurobindo | Acido Ibandronico Cinfa | Acido ibandronico combix | ACido Ibandronico Kern pharma | Acido ibandronico mylan | Acido ibandronico normon | Acido ibandronico qualigen | Acido ibandronico ranbaxy | Acido Ibandronico Ratiopharm | Acido ibandronico sandoz | Acido ibandronico stada | Acido ibandronico tecnigen | Acido ibandronico teva | Acido ibandronico vir | Bondenza | Bondronat | Bonviva</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva | Clastec | Ibamyl | Ibandronat Actavis | Ibandronat stada | Ibandronate Ratiopharm | Ibandronic acid accord</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Acide ibandronique teva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva | Iasibon | Ibandronic acid | Ibandronic acid accord | Ibandronic acid actavis | Ibandronic acid Kent | Ibandronic acid mylan | Ibandronic acid sandoz | Ibandronic acid teva | Quodixor</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Axibal | Bondronat | Bone free | Iasibon | Ibanate | Ibandronic acid Specifar | Ibondem | Ibosat | Ozilen | Sedropor | Spesostoun | Voliran</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonjenic | Bonviva</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonnedra | Bonosta | Bonviva | Ibadron | Ibandronat PharmaS | Ibandronat Sandoz | Ibat | Ostea</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonessa | Holmevis | Ibandronate pharmacenter | Ibandronic acid accord | Ibandronsav | Ibandronsav gentian generics | Ibandronsav sandoz | Ibandronsav Teva | Osagrand | Ossica | Phacebonate | Quodixor</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonefurbit | Bonviva | Ibandronic acid | Osbonelle | Quodixor</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bandrone | Bonrise | Egyban | Flurish | Gemidro | Iban plus | Idrofos | Idromet | Irbez | Monthiba | Vebalone</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Acido ibandronico | Acido ibandronico accord | Acido ibandronico actavis | Acido ibandronico aurobindo | Acido ibandronico bluefish | Acido ibandronico doc generici | Acido ibandronico germed | Acido ibandronico mylan | Acido ibandronico pensa | Acido ibandronico sandoz | Acido ibandronico tecnigen | Acido ibandronico teva | Acido ibandronico zentiva | Baxogar | Bondronat | Bonviva | Ibostofar</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bonviva</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Baron | Bondronat | Bonviva | Cadronate | I fos | Ibandro</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ahngook ibandronate sodium | Amicabone | Amikabon | Anabon | Bandron | Bandronate | Bonbis | Bondan | Bondex | Bondronat | Bonegard | Bonevega | Bonezoa | Boni M | Bonivan | Bonjenic | Bonviva | Dongkwang ibandronic acid | Droban | Drobone | Evebone | Gendron | Haniban | Ibabon | Ibandqual | Ibandren | Ibandron | Ibanel | Ibannate | Ibateron | Ibondens | Ibondro | Il yang ibandronate | Ironsan | Kyongbo ibandronate | Osmac | Proiban | Unibiba | Unibone | Vivadron | Yuyu ibandronate sodium</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Adromux | Bonafor | Bondronat | Bonviva</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Baxogar | Bondronat | Ibandronic acid briz | Ibandronic Acid Ingen Pharma | Ibandronic acid mylan | Osagrand | Ossica</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva | Ibandronate eg | Ibandronate mithra</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Baxogar | Bondronat | Iasibon | Ibandronic acid accord | Ibandronic acid ratiopharm | Ibandronic acid teva | Ivadron | Osagrand | Ossica</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Ibandro zenith</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acido ibandronico apotex | Bondronat | Bonviva | Dabran | Fosfonat</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva | Ibandroninezuur Actavis | Ibandroninezuur aurobindo | Ibandroninezuur Mylan | Ibandroninezuur Sandoz | Ibandroninezuur xiromed</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva | Ibandronsyre medical valley</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Bandrex | Bonames | Bonil | Bonviva | Brexell plus | Brexi plus | Dronaval | Ibames | Ibandra | Ibandroporosis | Ibonix | Idena | Ipexal | Maxibone | Oseban | Osteoban | Osteosyl | Resormes | Reumol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adronil | Bionic | Bondronat | Bonheal | Bonvir | Bonviva | Boonest | Filbone | Franjic | Ibandro | Ibnate | Ironic | Jupiter | Oseban | Osfit | Ostenate | Ronate | Winbendra</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Bonviva | Ibandronat Apotex | Ibandronat Polpharma | Ibandronic acid | Ibandronic Acid Aurovitas | Ibandronic acid mylan | Ibandronic acid teva | Kefort | Nucodran | Osagrand | Ossica | Ostone | Quodixor</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Boniva</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Acido ibandronico | Acido ibandronico actavis | Acido ibandronico alter | Acido ibandronico aurobindo | Acido ibandronico bluepharma | Acido ibandronico farmoz | Acido Ibandronico GP | Acido Ibandronico Pentafarma | Acido ibandronico pharmakern | Acido ibandronico teva | Baxogar | Bondronat | Etanorden</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Adromux | Benzidol | Bondronat | Bonviva | Dronaval | Femorel | Ibadrona | Idena | Layax | Recaxin | Tefal</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Bonviva</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Acid ibandronic accord | Acid ibandronic aurobindo | Acid ibandronic glenmark | Acid ibandronic sandoz | Acid ibandronic teva | Bondronat | Bonviva | Holmevis | Iasibon | Osagrand | Ossica | Quodixor</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva | Rezoviva</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Bonviva</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva | Iasibon | Ibandronat stada | Ibandronate Bluefish | Ibandronic acid accord | Ibandronic acid sandoz</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Bondronat</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Ibandronska kislina Teva</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva | Flastin | Gerousia | Iasibon | Ibandronat Actavis | Ibandronic acid mylan | Ibandronic acid stada | Ikametin | Kefort | Kyselina ibandronova Teva | Licobondrat | Osagrand | Ossica | Phacebonate</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva | Ibonate</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Bondronat</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Bonviva | Ibamax | Ibanos | Ibofix | Kemidat | Kemiva | Osiban | Sempriban</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bondronat | Keybone</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Bandrone | Bonablast | Bondronat | Ibandronic acid | Ibandronic acid Pharmex</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Adromux | Andromux | Femorel</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acido ibandronico | Acler | Bonviva | Denual | Ibandromet | Ibone | Idena</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aspen ibandronate | Bondronat | Boniva</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Bonviva</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3124942">
<a name="3124942"></a>Adami S, Bhalla AK, Dorizzi R, et al. The acute-phase response after bisphosphonate administration. <i>Calcif Tissue Int</i>. 1987;41(6):326-331. doi:10.1007/BF02556671<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/3124942/pubmed" id="3124942" target="_blank">3124942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26350171">
<a name="26350171"></a>Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research [published correction appears in <i>J Bone Miner Res</i>. 2016;31(10):1910]. <i>J Bone Miner Res</i>. 2016;31(1):16-35. doi:10.1002/jbmr.2708<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/26350171/pubmed" id="26350171" target="_blank">26350171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21736407">
<a name="21736407"></a>Aibar Arregui MA, de Escalante Yangüela B, Muñoz Villalengua M, Garcés Horna V. Esophageal stenosis caused by alendronate. <i>Rev Esp Enferm Dig</i>. 2011;103(6):338-339. doi:10.4321/s1130-01082011000600015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/21736407/pubmed" id="21736407" target="_blank">21736407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19371816">
<a name="19371816"></a>Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. <i>J Oral Maxillofac Surg</i>. 2009;67(5 Suppl):61-70. doi:10.1016/j.joms.2009.01.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/19371816/pubmed" id="19371816" target="_blank">19371816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16873332">
<a name="16873332"></a>American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy. <i>JADA.</i> 2006;137(8):1144-1150. http://jada.ada.org/article/S0002-8177(14)64960-6/pdf
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/16873332/pubmed" id="16873332" target="_blank">16873332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SafetyUpdate.1">
<a name="SafetyUpdate.1"></a>Author Unknown. Safety update: bone-building drugs: risks explained. <i>Consum Rep Health.</i> 2006;18(5):3.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15317823">
<a name="15317823"></a>Barrett J, Worth E, Bauss F, et al. Ibandronate: a clinical pharmacological and pharmacokinetic update. <i>J Clin Pharmacol.</i> 2004;44(9):951-965.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/15317823/pubmed" id="15317823" target="_blank">15317823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20534366">
<a name="20534366"></a>Bhalla AK. Management of osteoporosis in a pre-menopausal woman. <i>Best Pract Res Clin Rheumatol</i>. 2010;24(3):313-327.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/20534366/pubmed" id="20534366" target="_blank">20534366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30169557">
<a name="30169557"></a>Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N. Atypical femur fractures: Review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. <i>Endocr Rev</i>. 2019;40(2):333-368. doi:10.1210/er.2018-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/30169557/pubmed" id="30169557" target="_blank">30169557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32813950">
<a name="32813950"></a>Black DM, Geiger EJ, Eastell R, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. <i>N Engl J Med</i>. 2020;383(8):743-753. doi:10.1056/NEJMoa1916525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/32813950/pubmed" id="32813950" target="_blank">32813950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19318598">
<a name="19318598"></a>Blumentals WA, Harris ST, Cole RE, Huang L, Silverman SL. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate. <i>Ann Pharmacother</i>. 2009;43(4):577-585. doi:10.1345/aph.1L555<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/19318598/pubmed" id="19318598" target="_blank">19318598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12954579">
<a name="12954579"></a>Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. <i>Ann Oncol</i>. 2003;14(9):1399-1405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/12954579/pubmed" id="12954579" target="_blank">12954579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24256556">
<a name="24256556"></a>Bonilla IM, Vargas-Pinto P, Nishijima Y, et al. Ibandronate and ventricular arrhythmia risk [published online December 20, 2013]. <i>J Cardiovasc Electrophysiol</i>. 2014;25(3):299-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/24256556/pubmed" id="24256556" target="_blank">24256556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Boniva.2019.04">
<a name="Boniva.2019.04"></a>Boniva injection (ibandronate) [prescribing information]. South San Francisco, CA: Genentech USA Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BonivaTab.1">
<a name="BonivaTab.1"></a>Boniva tablets (ibandronate) [prescribing information]. South San Francisco, CA: Genentech USA, Inc; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32427503">
<a name="32427503"></a>Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. <i>Endocr Pract</i>. 2020;26(suppl 1):s1-s46. doi:10.4158/GL-2020-0524SUPPL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/32427503/pubmed" id="32427503" target="_blank">32427503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25182228">
<a name="25182228"></a>Cosman F, de Beur SJ, LeBoff MS, et al; National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/25182228/pubmed" id="25182228" target="_blank">25182228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16729277">
<a name="16729277"></a>Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. <i>Arthritis Rheum</i>. 2006;54(6):1838-1846. doi:10.1002/art.21918<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/16729277/pubmed" id="16729277" target="_blank">16729277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19851511">
<a name="19851511"></a>Derman R, Kohles JD, Babbitt A. Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment. <i>Clin Interv Aging</i>. 2009;4:357-365. doi:10.2147/cia.s5637<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/19851511/pubmed" id="19851511" target="_blank">19851511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15251160">
<a name="15251160"></a>Diel IJ, Body JJ, Lichinitser MR, et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. <i>Eur J Cancer.</i> 2004;40(11):1704-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/15251160/pubmed" id="15251160" target="_blank">15251160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19175968">
<a name="19175968"></a>Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy? <i>J Obstet Gynaecol Can</i>. 2008;30(12):1146-1148.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/19175968/pubmed" id="19175968" target="_blank">19175968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16000365">
<a name="16000365"></a>Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. <i>N Engl J Med.</i> 2005;353(1):99-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/16000365/pubmed" id="16000365" target="_blank">16000365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30907953">
<a name="30907953"></a>Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1595-1622. doi:10.1210/jc.2019-00221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/30907953/pubmed" id="30907953" target="_blank">30907953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19047674">
<a name="19047674"></a>Edwards BJ, Hellstein JW, Jacobsen PL, et al. Updated Recommendations for Managing the Care of Patients Receiving Oral Bisphosphonate Therapy: An Advisory Statement From the American Dental Association Council on Scientific Affairs. <i>J Am Dent Assoc.</i> 2008;139(12):1674-1677.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/19047674/pubmed" id="19047674" target="_blank">19047674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22381111">
<a name="22381111"></a>El-Safadi S, Wuesten O, Muenstedt K. Primary diagnosis of metastatic breast cancer in the third trimester of pregnancy: a case report and review of the literature. <i>J Obstet Gynaecol Res</i>. 2012;38(3):589-592.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/22381111/pubmed" id="22381111" target="_blank">22381111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2010">
<a name="FDA.2010"></a>FDA Safety Announcement. FDA drug safety communication: safety update for osteoporosis drugs, bisphosphonates, and atypical fractures. Published October 13, 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20508948">
<a name="20508948"></a>Filleul O, Crompot E, Saussez S. Bisphosphonate-Induced Osteonecrosis of the Jaw: A Review of 2,400 Patient Cases. <i>J Cancer Res Clin Oncol.</i> 2010;136(8):1117-1124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/20508948/pubmed" id="20508948" target="_blank">20508948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17614762">
<a name="17614762"></a>Galluzzo S, Santini D, Vincenzi B, et al. Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity. <i>Expert Opin Ther Targets</i>. 2007;11(7):941-954. doi:10.1517/14728222.11.7.941<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/17614762/pubmed" id="17614762" target="_blank">17614762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25404594">
<a name="25404594"></a>Green SB, Pappas AL. Effects of maternal bisphosphonate use on fetal and neonatal outcomes. <i>Am J Health Syst Pharm</i>. 2014;71(23):2029-2036.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/25404594/pubmed" id="25404594" target="_blank">25404594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28602783">
<a name="28602783"></a>Hall SF, Edmonds SW, Lou Y, et al. Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. <i>J Am Pharm Assoc</i> (2003). 2017;57(4):503-509. doi:10.1016/j.japh.2017.05.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/28602783/pubmed" id="28602783" target="_blank">28602783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16454811">
<a name="16454811"></a>Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. <i>J Oral Pathol Med</i>. 2006;35(3):155-160. doi:10.1111/j.1600-0714.2006.00391.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/16454811/pubmed" id="16454811" target="_blank">16454811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22041409">
<a name="22041409"></a>Hellstein JW, Adler RA, Edwards B, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. <i>J Am Dent Assoc.</i> 2011;142(11):1243-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/22041409/pubmed" id="22041409" target="_blank">22041409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hellstein.1">
<a name="Hellstein.1"></a>Hellstein JW, Adler RA, Edwards B, et al. Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Recommendations From the American Dental Association Council on Scientific Affairs. 2011. http://www.ada.org/sections/professionalResources/pdfs/topics_ARONJ_report.pdf. Accessed February 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26242893">
<a name="26242893"></a>Hoskin P, Sundar S, Reczko K, et al. A multicenter randomized trial of ibandronate compared with single-dose radiotherapy for localized metastatic bone pain in prostate cancer.<i> J Natl Cancer Inst</i>. 2015;107(10).<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/26242893/pubmed" id="26242893" target="_blank">26242893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>IOM (Institute of Medicine). <i>Dietary Reference Intakes for Calcium and Vitamin D.</i> Washington, DC: The National Academies Press; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25710950">
<a name="25710950"></a>Katsarelis H, Shah NP, Dhariwal DK, Pazianas M. Infection and medication-related osteonecrosis of the jaw. <i>J Dent Res</i>. 2015;94(4):534-539. doi:10.1177/0022034515572021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/25710950/pubmed" id="25710950" target="_blank">25710950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25414052">
<a name="25414052"></a>Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. <i>J Bone Miner Res.</i> 2015; 30(1):3-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/25414052/pubmed" id="25414052" target="_blank">25414052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20674418">
<a name="20674418"></a>Kharazmi M, Sjöqvist K, Rizk M, Warfvinge G. Oral ulcer associated with alendronate: a case report. <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i>. 2010;110(6):e11-e13. doi:10.1016/j.tripleo.2010.04.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/20674418/pubmed" id="20674418" target="_blank">20674418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21816532">
<a name="21816532"></a>Kharazmi M, Sjöqvist K, Warfvinge G. Oral ulcers, a little known adverse effect of alendronate: review of the literature.<i> J Oral Maxillofac Surg</i>. 2012;70(4):830-836. doi:10.1016/j.joms.2011.03.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/21816532/pubmed" id="21816532" target="_blank">21816532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17663640">
<a name="17663640"></a>Khosla S, Burr D, Cauley J, et al; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. <i>J Bone Miner Res</i>. 2007;22(10):1479-1491. doi:10.1359/jbmr.0707onj<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/17663640/pubmed" id="17663640" target="_blank">17663640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15765619">
<a name="15765619"></a>Lanza FL. Gastrointestinal adverse effects of bisphosphonates: etiology, incidence and prevention. <i>Treat Endocrinol</i>. 2002;1(1):37-43. Erratum in:<i> Treat Endocrinol</i>. 2002;1(4):210. doi:10.2165/00024677-200201010-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/15765619/pubmed" id="15765619" target="_blank">15765619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19059370">
<a name="19059370"></a>Levy S, Fayez I, Taguchi N, et al. Pregnancy outcome following in utero exposure to bisphosphonates. <i>Bone</i>. 2009;44(3):428-430.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/19059370/pubmed" id="19059370" target="_blank">19059370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18498910">
<a name="18498910"></a>Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. <i>Clin Ther</i>. 2008;30(4):605-621. doi:10.1016/j.clinthera.2008.04.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/18498910/pubmed" id="18498910" target="_blank">18498910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lewiecki.1">
<a name="Lewiecki.1"></a>Lewiecki EM. Prevention of osteoporosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21504254">
<a name="21504254"></a>Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis. <i>Drugs</i>. 2011;71(6):791-814. doi:10.2165/11585470-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/21504254/pubmed" id="21504254" target="_blank">21504254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19772941">
<a name="19772941"></a>Lo JC, O'Ryan FS, Gordon NP, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. <i>J Oral Maxillofac Surg.</i> 2010;68(2):243-253.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/19772941/pubmed" id="19772941" target="_blank">19772941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31539355">
<a name="31539355"></a>Machairiotis N, Ntali G, Kouroutou P, Michala L. Clinical evidence of the effect of bisphosphonates on pregnancy and the infant. <i>Horm Mol Biol Clin Investig</i>. 2019;40(2). doi:10.1515/hmbci-2019-0021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/31539355/pubmed" id="31539355" target="_blank">31539355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20061894">
<a name="20061894"></a>Management of Osteoporosis in Postmenopausal Women: 2010 Position Statement of The North American Menopause Society. <i>Menopause.</i> 2010;17(1):25-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/20061894/pubmed" id="20061894" target="_blank">20061894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31893493">
<a name="31893493"></a>Marchand D, Loshak H. Duration of bisphosphonate treatment for patients with osteoporosis: A review of clinical effectiveness and guidelines [Internet]. Ottawa (ON): <i>Canadian Agency for Drugs and Technologies in Health</i>; 2019 Oct 4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/31893493/pubmed" id="31893493" target="_blank">31893493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12966493">
<a name="12966493"></a>Marx RE. Pamidronate (<i>Aredia</i>) and zoledronate (<i>Zometa</i>) induced avascular necrosis of the jaws: a growing epidemic. <i>J Oral Maxillofac Surg</i>. 2003;61(9):1115-1117. doi:10.1016/s0278-2391(03)00720-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/12966493/pubmed" id="12966493" target="_blank">12966493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16243172">
<a name="16243172"></a>Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. <i>J Oral Maxillofac Surg.</i> 2005;63(11):1567-1575.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/16243172/pubmed" id="16243172" target="_blank">16243172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17307586">
<a name="17307586"></a>Mavrokokki T, Cheng A, Stein B, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. <i>J Oral Maxillofac Surg.</i> 2007;65(3):415-423.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/17307586/pubmed" id="17307586" target="_blank">17307586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16007327">
<a name="16007327"></a>Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. <i>J Bone Miner Res</i>. 2005;20(8):1315-1322. doi:10.1359/JBMR.050313<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/16007327/pubmed" id="16007327" target="_blank">16007327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26037642">
<a name="26037642"></a>Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. <i>BMJ</i>. 2015;350:h2723. doi:10.1136/bmj.h2723<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/26037642/pubmed" id="26037642" target="_blank">26037642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27112533">
<a name="27112533"></a>Modi A, Sajjan S, Michael Lewiecki E, Harris ST, Papadopoulos Weaver J. Relationship between gastrointestinal events and compliance with osteoporosis therapy: An administrative claims analysis of the US managed care population. <i>Clin Ther</i>. 2016;38(5):1074-1080. doi:10.1016/j.clinthera.2016.03.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/27112533/pubmed" id="27112533" target="_blank">27112533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25866298">
<a name="25866298"></a>Modi A, Siris ES, Steve Fan CP, Sajjan S. Gastrointestinal events among patients initiating osteoporosis therapy: A retrospective administrative claims database analysis. <i>Clin Ther</i>. 2015;37(6):1228-1234. doi:10.1016/j.clinthera.2015.03.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/25866298/pubmed" id="25866298" target="_blank">25866298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22778283">
<a name="22778283"></a>Munigoti S, Frazer R, Rees A, Blackshaw G, Thomas G, Roberts A. A rare complication with a single dose of alendronate. <i>BMJ Case Rep</i>. 2010;2010:bcr0220102738. doi:10.1136/bcr.02.2010.2738<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/22778283/pubmed" id="22778283" target="_blank">22778283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32535678">
<a name="32535678"></a>Ng TL, Tu MM, Ibrahim MFK, et al. Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. <i>Support Care Cancer</i>. 2021;29(2):925-943. doi:10.1007/s00520-020-05556-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/32535678/pubmed" id="32535678" target="_blank">32535678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30393090">
<a name="30393090"></a>Nicolatou-Galitis O, Schiødt M, Mendes RA, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. <i>Oral Surg Oral Med Oral Pathol Oral Radiol</i>. 2019;127(2):117-135. doi: 10.1016/j.oooo.2018.09.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/30393090/pubmed" id="30393090" target="_blank">30393090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34448749">
<a name="34448749"></a>North American Menopause Society. Management of osteoporosis in postmenopausal women: the 2021 position statement of the North American Menopause Society. <i>Menopause</i>. 2021;28(9):973-997. doi:10.1097/GME.0000000000001831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/34448749/pubmed" id="34448749" target="_blank">34448749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18045781">
<a name="18045781"></a>Olson K, Van Poznak C. Significance and impact of bisphosphonate-induced acute phase responses. <i>J Oncol Pharm Pract</i>. 2007;13(4):223-229. doi:10.1177/1078155207080806<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/18045781/pubmed" id="18045781" target="_blank">18045781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19570737">
<a name="19570737"></a>Papapetrou PD. Bisphosphonate-associated adverse events. <i>Hormones</i> (Athens). 2009;8(2):96-110. doi:10.14310/horm.2002.1226<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/19570737/pubmed" id="19570737" target="_blank">19570737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21343577">
<a name="21343577"></a>Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. <i>JAMA</i>. 2011;305(8):783-789. doi:10.1001/jama.2011.190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/21343577/pubmed" id="21343577" target="_blank">21343577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21343270">
<a name="21343270"></a>Paul AK, Seetharaman M. Esophageal stricture associated with alendronate use. <i>CMAJ</i>. 2011;183(7):E429. doi:10.1503/cmaj.100415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/21343270/pubmed" id="21343270" target="_blank">21343270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9157773">
<a name="9157773"></a>Pecherstorfer M, Ludwig H, Schlosser K, Buck S, Huss HJ, Body JJ. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection.<i> J Bone Miner Res</i>. 1996;11(5):587-593. doi:10.1002/jbmr.5650110506<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/9157773/pubmed" id="9157773" target="_blank">9157773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17163265">
<a name="17163265"></a>Pecherstorfer M, Rivkin S, Body JJ, et al. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. <i>Clin Drug Investig</i>. 2006;26(6):315-322.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/17163265/pubmed" id="17163265" target="_blank">17163265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12783289">
<a name="12783289"></a>Pecherstorfer M, Steinhauer EU, Rizzoli R, et al. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. <i>Support Care Cancer. </i>2003;11(8):539-547.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/12783289/pubmed" id="12783289" target="_blank">12783289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16678644">
<a name="16678644"></a>Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. <i>Clin Ther</i>. 2006;28(2):236-242. doi:10.1016/j.clinthera.2006.01.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/16678644/pubmed" id="16678644" target="_blank">16678644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32453819">
<a name="32453819"></a>Pepe J, Body JJ, Hadji P, et al. Osteoporosis in premenopausal women: a clinical narrative review by the ECTS and the IOF [published online May 26, 2020]. <i>J Clin Endocrinol Metab</i>. doi:10.1210/clinem/dgaa306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/32453819/pubmed" id="32453819" target="_blank">32453819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22885424">
<a name="22885424"></a>Pereira RM, Carvalho JF, Paula AP, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. <i>Rev Bras Reumatol</i>. 2012;52(4):580-593.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/22885424/pubmed" id="22885424" target="_blank">22885424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28299378">
<a name="28299378"></a>Popp AW, Senn R, Curkovic I, et al. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate. <i>Osteoporos Int</i>. 2017;28(6):1995-2002. doi: 10.1007/s00198-017-3992-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/28299378/pubmed" id="28299378" target="_blank">28299378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9010041">
<a name="9010041"></a>Ralston SH, Thiébaud D, Herrmann Z, et al. Dose-response study of Ibandronate in the treatment of cancer-associated hypercalcaemia. <i>Br J Cancer.</i> 1997;75(2):295-300. doi:10.1038/bjc.1997.48<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/9010041/pubmed" id="9010041" target="_blank">9010041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12686715">
<a name="12686715"></a>Rosen CJ, Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency.<i> N Engl J Med</i>. 2003;348(15):1503-1504. doi:10.1056/NEJM200304103481521<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/12686715/pubmed" id="12686715" target="_blank">12686715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12686715">
<a name="12686715"></a>Rosen HN, Drezner MK. Overview of the management of osteoporosis in postmenopausal women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 20, 2022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/12686715/pubmed" id="12686715" target="_blank">12686715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ruggiero.1">
<a name="Ruggiero.1"></a>Ruggiero S, Gralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. <i>J Clin Oncol. </i>2006;2(1):7-14.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20924014">
<a name="20924014"></a>Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. <i>JAMA.</i> 2010;304(13):1480-1484.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/20924014/pubmed" id="20924014" target="_blank">20924014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shane.2022">
<a name="Shane.2022"></a>Shane E. Treatment of hypercalcemia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed August 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23712442">
<a name="23712442"></a>Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. <i>J Bone Miner Res</i>. 2014;29(1):1-23. doi:10.1002/jbmr.1998<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/23712442/pubmed" id="23712442" target="_blank">23712442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20842676">
<a name="20842676"></a>Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. <i>J Bone Miner Res.</i> 2010;25(11):2267-2294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/20842676/pubmed" id="20842676" target="_blank">20842676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23184667">
<a name="23184667"></a>Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice. <i>Clin Drug Investig</i>. 2013;33(2):117-122. doi:10.1007/s40261-012-0041-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/23184667/pubmed" id="23184667" target="_blank">23184667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24577348">
<a name="24577348"></a>Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. <i>Osteoporos Int</i>. 2014;25(5):1439-1443. doi: 10.1007/s00198-014-2655-z.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/24577348/pubmed" id="24577348" target="_blank">24577348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30171300">
<a name="30171300"></a>Sokal A, Elefant E, Leturcq T, Beghin D, Mariette X, Seror R. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. <i>Osteoporos Int</i>. 2019;30(1):221-229.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/30171300/pubmed" id="30171300" target="_blank">30171300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31168902">
<a name="31168902"></a>Song X, Guo Y, Zhao H. Erythema multiforme caused by ibandronate sodium: A rare case report. <i>Dermatol Ther</i>. 2019;32(4):e12984. doi:10.1111/dth.12984<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/31168902/pubmed" id="31168902" target="_blank">31168902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22281884">
<a name="22281884"></a>Stathopoulos IP, Liakou CG, Katsalira A, et al. The use of bisphosphonates in women prior to or during pregnancy and lactation. <i>Hormones (Athens)</i>. 2011;10(4):280-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/22281884/pubmed" id="22281884" target="_blank">22281884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15673803">
<a name="15673803"></a>Stewart AF. Clinical practice. Hypercalcemia associated with cancer. <i>N Engl J Med.</i> 2005;352(4):373-379.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/15673803/pubmed" id="15673803" target="_blank">15673803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24287510">
<a name="24287510"></a>Tadrous M, Wong L, Mamdani MM, et al. Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. <i>Osteoporos Int</i>. 2014;25(4):1225-1235. doi:10.1007/s00198-013-2576-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/24287510/pubmed" id="24287510" target="_blank">24287510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16547070">
<a name="16547070"></a>Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. <i>Ann Oncol</i>. 2006;17(6):897-907. doi:10.1093/annonc/mdj105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/16547070/pubmed" id="16547070" target="_blank">16547070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12947959">
<a name="12947959"></a>Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. <i>Am J Med</i>. 2003;115(3):209-216. doi:10.1016/s0002-9343(03)00362-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/12947959/pubmed" id="12947959" target="_blank">12947959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15823760">
<a name="15823760"></a>Tripathy D, Body JJ, Bergstrom B. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. <i>Clin Ther.</i> 2004;26(12):1947-1959.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/15823760/pubmed" id="15823760" target="_blank">15823760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16873439">
<a name="16873439"></a>Van den Wyngaert T, Huizing MT, Vermorken JB. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? <i>Ann Oncol</i>. 2006;17(8):1197-204. doi:10.1093/annonc/mdl294<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/16873439/pubmed" id="16873439" target="_blank">16873439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21343561">
<a name="21343561"></a>Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer. <i>J Clin Oncol.</i> 2011;29(9):1221-1227.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/21343561/pubmed" id="21343561" target="_blank">21343561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20173017">
<a name="20173017"></a>Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. <i>J Clin Endocrinol Metab</i>. 2010;95(4):1555-1565. doi: 10.1210/jc.2009-1947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/20173017/pubmed" id="20173017" target="_blank">20173017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19118315">
<a name="19118315"></a>Wysowski DK. Reports of Esophageal Cancer With Oral Bisphosphonate Use. <i>N Engl J Med.</i> 2009;360(1):89-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/19118315/pubmed" id="19118315" target="_blank">19118315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30626809">
<a name="30626809"></a>Yamamoto K, Kishino M, Nakamura S, Tokushige K. Symptoms and upper gastrointestinal mucosal injury associated with bisphosphonate therapy. <i>Intern Med</i>. 2019;58(8):1049-1056. doi:10.2169/internalmedicine.1271-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/30626809/pubmed" id="30626809" target="_blank">30626809</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8887 Version 310.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
